AstraZeneca has confirmed that contact between CEO Pascal Soriot and Thailand Prime Minister Prayut Chan-o-cha took place today, to discuss ongoing collaboration on Thailand’s efforts against the pandemic.
During their call, Mr Soriot and the Prime Minister discussed the common goal of bringing an end to the pandemic in Thailand and internationally. The discussion included accelerated supply of COVID-19 Vaccine AstraZeneca in Thailand, with the aim of delivering 61 million doses by the end of this year. The company will continue to work closely with the Department of Disease Control to support the mass vaccination programme.
Also covered was ongoing discussion on the supply of COVID-19 vaccine doses to Thailand in 2022, including AstraZeneca’s variant vaccine candidate AZD2816, which is currently being developed.
The COVID-19 Vaccine AstraZeneca, (ChAdOx1-S [Recombinant]), formerly AZD1222, was co-invented by the University of Oxford and its spin-off company, Vaccitech. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.
During their call, Mr Soriot and the Prime Minister discussed the common goal of bringing an end to the pandemic in Thailand and internationally. The discussion included accelerated supply of COVID-19 Vaccine AstraZeneca in Thailand, with the aim of delivering 61 million doses by the end of this year. The company will continue to work closely with the Department of Disease Control to support the mass vaccination programme.
Also covered was ongoing discussion on the supply of COVID-19 vaccine doses to Thailand in 2022, including AstraZeneca’s variant vaccine candidate AZD2816, which is currently being developed.
The COVID-19 Vaccine AstraZeneca, (ChAdOx1-S [Recombinant]), formerly AZD1222, was co-invented by the University of Oxford and its spin-off company, Vaccitech. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.